GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

crovalimab   Click here for help

GtoPdb Ligand ID: 12790

Synonyms: crovalimab-akkz | Piasky® | RG-6107 | RG6107 | Senkai® (China) | SKY59
Approved drug Immunopharmacology Ligand
crovalimab is an approved drug (China NMPA, FDA & EMA (2024))
Compound class: Antibody
Comment: Crovalimab (SKY59/RG6107) is a long-acting anti-C5 recycling monoclonal antibody [2,6]. The antibody is engineered to bind C5 in a pH-dependent manner. It binds strongly to C5 in the plasma, but in the acidic conditions within the endosome the antibody-C5 immune complex dissociates. The free antibody is re-cycled and can bind more plasma C5, to provide sustained complement inhibition. The C5 released in the endosome is trafficked to the lysosome for degradation. Crovalimab is proposed as a treatment for complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) [5] and Lupus nephritis.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2024)  |  EU EMA (2024)  |  US FDA (2024)
International Nonproprietary Names Click here for help
INN number INN
10882 crovalimab
Synonyms Click here for help
crovalimab-akkz | Piasky® | RG-6107 | RG6107 | Senkai® (China) | SKY59
Database Links Click here for help
GtoPdb PubChem SID 483123338
Search PubMed clinical trials crovalimab
Search PubMed titles crovalimab
Search PubMed titles/abstracts crovalimab